Keywords: il-12, trials, cancer, therapy, interleukin-12, being, developed
IL-12 In Trials As Cancer Therapy
Article | 24 April 1995
Interleukin-12, which is being developed by Genetics Institute and Hoffmann-La Roche and is now undergoing initial toxicity and dose-ranging studies ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
